1. Molecules. 2016 Feb 16;21(2):221. doi: 10.3390/molecules21020221.

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Famiglini V(1), Silvestri R(2).

Author information:
(1)Institute Pasteur Italy-Fondazione Cenci Bolognetti, Dipartimento di Chimica 
e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, 
I-00185 Roma, Italy. valeria.famiglini@uniroma1.it.
(2)Institute Pasteur Italy-Fondazione Cenci Bolognetti, Dipartimento di Chimica 
e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, 
I-00185 Roma, Italy. romano.silvestri@uniroma1.it.

Chiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of 
great interest since one enantiomer is often more potent than the corresponding 
counterpart against the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant 
strains. This review exemplifies the various studies made to investigate the 
effect of chirality on the antiretroviral activity of top HIV-1 NNRTI compounds, 
such as nevirapine (NVP), efavirenz (EFV), alkynyl- and alkenylquinazolinone 
DuPont compounds (DPC), diarylpyrimidine (DAPY), 
dihydroalkyloxybenzyloxopyrimidine (DABO), phenethylthiazolylthiourea (PETT), 
indolylarylsulfone (IAS), arylphosphoindole (API) and trifluoromethylated indole 
(TFMI) The chiral separation, the enantiosynthesis, along with the biological 
properties of these HIV-1 NNRTIs, are discussed.

DOI: 10.3390/molecules21020221
PMCID: PMC6273187
PMID: 26891289 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no conflict of interest.